Rua Releases Annual Report for Year Ended 30 June 2025

Rua Bioscience releases Annual Report for the Year Ended 30 June 2025

Highlights: FY25 revenue increased to $1.90m (up from $0.32m in FY24) with strong momentum expected to continue into FY26.

Tairawhiti, New Zealand – Rua Bioscience (NZX: RUA) has today released its Annual Report for the 12 months ended 30 June 2025 (FY25).

The Annual Report is attached and available on Rua’s website: www.ruabio.com/annual-report.

The Annual Report provides an overview of Rua’s year, focused on the execution of its highly scalable strategy, anchored in genetics and distribution, which is now translating into tangible commercial results.

Rua’s financial performance was previously highlighted with the release of our unaudited financial statements on 1 September 2025. Rua reported a marked increase in revenue and a significantly reduced loss before tax of $3.46m (FY25: $13.72m). Revenue rose to $1.90m (FY24: $0.32m), with revenue from customer reaching $1.51m (FY24: $86K).

It should be noted that although Rua have increased revenue and received $1.5m from shareholders during the financial year, forecasts for the next 12 months indicate that the Group will not have sufficient cash to meet its minimum expenditure commitments and support its current levels of activity without undertaking additional action. For further information and context please refer to the Going Concern Disclosure (Note 2(f) in the Financial Statements).

The Directors continue to believe Rua is well positioned for growth, supported by shareholder backing and expanding sales pipelines in key global markets.

Subsequent operational and Financial Update

Rua has entered FY26 with strong momentum, underpinned by continued shareholder support and record sales across multiple markets.

Following the balance date of 30 June 2025, the company secured a further $1.26m through a combination of equity and debt, primarily used to purchase inventory to accelerate growth in key markets.

Operational highlights since 30 June 2025 include:

• Australia: Record monthly sales as a result of expanding portfolio and key clinic relationships.

• New Zealand: Record monthly sales were achieved in July in line with new product launches.

• Germany: Launch of Rua’s first New Zealand grown product, leveraging legacy genetics and delivering on the strategy to take New Zealand genetics to key export markets.

• United Kingdom: Growing sales in this early-stage market, with increasing engagement with key clinics and prescribers.

• Czechia: Market entry achieved with the first product launched, securing valuable first-mover advantage and a pipeline for expansion.

Further capital requirements

To support its ongoing growth, Rua will require additional capital to support growing sales demand. The Board is working with its key shareholders and advisors on further capital raise options.

“Rua has achieved significant commercial milestones and is now generating revenue in five key markets”, said Paul Nake, Chief Executive Officer. “We are extremely well placed to build on this momentum and further capital will provide the runway we need to accelerate growth and deliver on our strategy”.

Outlook

Rua is expecting sales momentum to continue throughout FY26 with revenue growth anticipated from both established and emerging markets.

The company remains focused on accelerating commercial performance, strengthening international partnerships and delivering on its highly scalable strategy. Alongside this, Rua will continue to uphold its kaupapa by delivering social impact in Tairawhiti and beyond.

“Rua’s waka is set on a clear course”, said Paul Naske, Chief Executive Officer. “We are confident in the opportunities ahead and committed to building long-term, sustainable value for our shareholders and our people”.

ENDS

For more information, please visit www.ruabio.com or contact

Paul Naske
Chief Executive Officer
+64 (21) 445 154
www.ruabio.com

---

Announcement PDF